ArticleJournal of diabetes investigation2025
Analysis of the Japanese gestational diabetes mellitus diagnostic strategy during the coronavirus disease 2019 pandemic using DREAMBee study data.
Article in Journal of diabetes investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Association between gestational diabetes mellitus and risk of breast cancer: a systematic review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIMS/
introductionWe evaluated a simple diagnostic gestational diabetes mellitus (GDM) strategy (Japanese COVID-19 GDM strategy) published by the Japanese Society of Diabetes and Pregnancy using GDM group data from the Diabetes and Pregnancy Outcomes for Mother and Baby (DREAMBee) study. MATERIALS AND
methodsThe study included 803 mothers with GDM diagnosed after 24 gestational weeks using an oral glucose tolerance test and 1,356 with normal glucose tolerance (NGT) from the DREMBee study. They were reclassified by the Japanese COVID-19 GDM strategies (COVID-19 GDM and COVID-19 NGT) using glycated hemoglobin (HbA1c) and random plasma glucose or fasting plasma glucose (FPG) levels. We evaluated the usefulness of the Japanese COVID-19 GDM strategy and investigated the parameters for diagnosing GDM managed with insulin therapy.
resultsParticipants (n = 2,159) were assigned to COVID-19 GDM (n = 413) and COVID-19 NGT (n = 1,746) groups. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the Japanese COVID-19 GDM strategy were 35.4, 90.5, 68.9, and 70.3%, respectively. When the risk factors for insulin therapy were analyzed using a regression model, HbA1c and FPG levels were risk factors for GDM with insulin therapy (P < 0.0001). The cut-off value of HbA1c was 5.4% (sensitivity, 0.69; specificity, 0.66; PPV, 0.11; NPV, 0.97), and that of FPG was 86 mg/dL (sensitivity, 0.60; specificity, 0.77; PPV, 0.16; NPV, 0.96).
conclusionsThe Japanese COVID-19 GDM strategy for GDM diagnosis after 24 weeks of gestation might be useful in emergency situations. However, further analysis of GDM outcomes diagnosed using this approach is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.